Empery reports 4.99% stake in Precision BioSciences
Empery Asset Management, LP and Ryan M. Lane report beneficial ownership of 1,314,393 shares of Precision BioSciences, Inc. common stock, including 538,300 shares issuable upon exercise of warrants.
Empery Asset Management, LP and Ryan M. Lane report beneficial ownership of 1,314,393 shares of Precision BioSciences, Inc. common stock, including 538,300 shares issuable upon exercise of warrants. This represents 4.99% of the common stock, based on 25,802,247 shares outstanding as of April 30, 2026.
The warrants contain a 4.99% beneficial ownership blocker, so the holders cannot exercise them to the extent their ownership would exceed 4.99% of the outstanding shares. Voting and dispositive power over these shares is shared, with no sole power reported. The filing confirms ownership of 5 percent or less of the class.
Positive
None.
Negative
None.
Key Figures
Beneficially owned shares:1,314,393 sharesShares underlying warrants:538,300 sharesOwnership percentage:4.99%+3 more
6 metrics
Beneficially owned shares1,314,393 sharesCommon Stock beneficially owned by the Reporting Persons, including shares underlying warrants
Shares underlying warrants538,300 sharesCommon Stock issuable upon exercise of warrants held by funds managed by Empery
Ownership percentage4.99%Percent of Precision BioSciences Common Stock class beneficially owned by the Reporting Persons
Shares outstanding baseline25,802,247 sharesCommon Stock outstanding as of April 30, 2026, from the company’s Form 10-Q
Sole voting power0 sharesNumber of shares over which each Reporting Person has sole voting power
Shared voting power1,314,393 sharesNumber of shares over which each Reporting Person has shared voting power
Key Terms
beneficial owner, Blocker, shared dispositive power, beneficial ownership of 5 percent or less of a class
4 terms
beneficial ownerfinancial
"may be deemed to be the beneficial owner of all of the Common Stock"
A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.
Blockerfinancial
"cannot exercise the Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 4.99% of the outstanding shares of Common Stock (the "Blocker")"
shared dispositive powerfinancial
"Shared Dispositive Power 1,314,393.00"
beneficial ownership of 5 percent or less of a classfinancial
"Item 5. | Ownership of 5 Percent or Less of a Class. | Ownership of 5 percent or less of a class"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of Precision BioSciences (DTIL) shares does Empery Asset Management report owning?
Empery Asset Management and Ryan M. Lane report beneficial ownership of 4.99% of Precision BioSciences common stock. This percentage is based on 25,802,247 shares outstanding as of April 30, 2026 and includes shares issuable upon warrant exercise subject to a blocker.
How many Precision BioSciences (DTIL) shares are beneficially owned according to this Schedule 13G/A?
The reporting persons disclose beneficial ownership of 1,314,393 shares of Precision BioSciences common stock. This figure includes 538,300 shares issuable upon exercise of warrants, subject to a 4.99% beneficial ownership blocker limiting further exercises.
What is the warrant position disclosed in the Precision BioSciences (DTIL) Schedule 13G/A amendment?
The filing states that the reporting persons’ stake includes 538,300 shares of Precision BioSciences common stock issuable upon exercise of warrants. These warrants are subject to a 4.99% Blocker that prevents exercises pushing ownership above 4.99% of outstanding shares.
On what share count is the 4.99% Precision BioSciences (DTIL) ownership calculation based?
The 4.99% beneficial ownership is calculated using 25,802,247 shares of Precision BioSciences common stock outstanding as of April 30, 2026. That share count comes from the company’s Form 10-Q for the quarter ended March 31, 2026.
Do Empery Asset Management and Ryan M. Lane control voting and dispositive power over DTIL shares?
They report 0 sole voting and dispositive power and 1,314,393 shared voting and dispositive power over Precision BioSciences shares. The investment manager and related entities may be deemed beneficial owners but include standard beneficial ownership disclaimer language.
What does the Schedule 13G/A say about owning 5 percent or less of Precision BioSciences (DTIL)?
The filing expressly states Ownership of 5 percent or less of a class for Precision BioSciences common stock. This aligns with the reported 4.99% beneficial ownership, reflecting the impact of the 4.99% Blocker on warrant exercisability.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
Precision BioSciences, Inc.
(Name of Issuer)
Common Stock, $0.000005 par value per share
(Title of Class of Securities)
74019P207
(CUSIP Number)
06/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
74019P207
1
Names of Reporting Persons
Empery Asset Management, LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,314,393.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,314,393.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,314,393.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.99 %
12
Type of Reporting Person (See Instructions)
IA, PN
Comment for Type of Reporting Person: Includes 538,300 shares of Common Stock issuable upon exercise of Warrants (as defined in Item 2(a))
SCHEDULE 13G
CUSIP Number(s):
74019P207
1
Names of Reporting Persons
Ryan M. Lane
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,314,393.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,314,393.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,314,393.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.99 %
12
Type of Reporting Person (See Instructions)
HC, IN
Comment for Type of Reporting Person: Includes 538,300 shares of Common Stock issuable upon exercise of Warrants (as defined in Item 2(a))
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Precision BioSciences, Inc.
(b)
Address of issuer's principal executive offices:
302 East Pettigrew Street, Suite A-100, Durham, NC 27701
Item 2.
(a)
Name of person filing:
This statement is filed by the entities and persons listed below, who are collectively referred to herein as "Reporting Persons," with respect to Common Stock, par value $0.000005 per share (the "Common Stock") and Common Stock issuable upon exercise of warrants ("Warrants") of Precision BioSciences, Inc., a Delaware corporation (the "Company"):
(i) Empery Asset Management, LP (the "Investment Manager"), with respect to the Common Stock held by, and the Common Stock issuable upon exercise of the Warrants held by, funds to which the Investment Manager serves as investment manager (the "Empery Funds"); and
(ii) Mr. Ryan M. Lane ("Mr. Lane"), with respect to the Common Stock held by, and the Common Stock issuable upon exercise of the Warrants held by, the Empery Funds.
The Investment Manager serves as the investment manager to each of the Empery Funds. Mr. Lane (the "Reporting Individual") is the managing member of a limited liability company that is the managing member of Empery AM GP, LLC (the "General Partner"), the general partner of the Investment Manager.
(b)
Address or principal business office or, if none, residence:
The address of the business office of each of the Reporting Persons is:
1 Rockefeller Plaza, Suite 1205
New York, New York 10020
(c)
Citizenship:
Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.
(d)
Title of class of securities:
Common Stock, $0.000005 par value per share
(e)
CUSIP No.:
74019P207
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 25,802,247 shares of Common Stock outstanding as of April 30, 2026, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026, filed with the Securities and Exchange Commission on May 5, 2026 and assumes exercise of the Warrants (subject to the Blocker (as defined below)).
Pursuant to the terms of the Warrants, the Reporting Persons cannot exercise the Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 4.99% of the outstanding shares of Common Stock (the "Blocker"), and the shares of Common Stock listed as beneficially owned in Rows 6, 8 and 9 of the cover page for each Reporting Person and the percentage set forth in Row 11 of the cover page for each Reporting Person give effect to the Blockers. Consequently, as of the date of the event which requires the filing of this statement, the Reporting Persons were not able to exercise all of the Warrants due to the Blocker.
The Investment Manager, which serves as the investment manager to the Empery Funds, may be deemed to be the beneficial owner of all of the Common Stock held by, and the Common Stock issuable upon exercise of the Warrants (subject to the Blocker) held by, the Empery Funds. The Reporting Individual, as the managing member of the limited liability company that is the managing member of the General Partner of the Investment Manager with the power to exercise investment discretion, may be deemed to be the beneficial owner of all of the Common Stock held by, and the Common Stock issuable upon exercise of the Warrants (subject to the Blocker) held by, the Empery Funds. The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the Common Stock owned by another Reporting Person. Each of the Empery Funds and the Reporting Individual hereby disclaims any beneficial ownership of any such Common Stock.
(b)
Percent of class:
4.99%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(ii) Shared power to vote or to direct the vote:
The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(iii) Sole power to dispose or to direct the disposition of:
The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(iv) Shared power to dispose or to direct the disposition of:
The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
